Yükleniyor... / Loading...
This study investigates the use of methylation markers in patients with early-stage non-small cell lung cancer who are not suitable for, or decline, surgical resection and are treated with a co-ablation system therapy. It enrolls patients aged 18 to 85 whose tumor size is within defined limits. It is an observational study with no assigned phase and is currently recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Diagnosed with non-small cell lung cancer by histopathology/clinical diagnosis; assessed by MDT as not suitable or refusing open or thoracoscopic resection surgery. * Age 18-85 years old, gender unrestricted. * The maximum diameter of the tumor is ≤ 5 cm (peripheral type) or ≤ 3 cm (central type), and the distance from major blood vessels/trachea is ≥ 1 cm. * Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1, with an expected survival period of ≥ 6 months. * The subjects should have clear case information, including age, gender, and clinical diagnosis, etc. Exclusion Criteria: * Those with a history of other malignant tumors or autoimmune diseases。 * Pregnant or lactating women; or patients with lung cancer who were negative for methylation before treatment. * Patients with clinical or pathological diagnosis of lung metastatic cancer. * Ppatients with multiple nodules and the current treatment cannot completely address all positive nodules. * Patients whose clinical information or follow-up during the study may not be completed; and other factors that the researcher deems unsuitable for participation in this study.